Cidara Continues To Work In Collaboration With Janssen To Complete Phase 1 (NCT05285137 And NCT05619536) And Phase 2a (NCT05523089) Clinical Trials
Portfolio Pulse from Benzinga Newsdesk
Cidara Therapeutics is continuing its collaboration with Janssen to complete Phase 1 and Phase 2a clinical trials. The trials are registered under the identifiers NCT05285137, NCT05619536, and NCT05523089.
July 20, 2023 | 9:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cidara Therapeutics' ongoing collaboration with Janssen for clinical trials may have an impact on its stock.
The continuation of the collaboration between Cidara Therapeutics and Janssen for the completion of Phase 1 and Phase 2a clinical trials is a positive development for the company. This could potentially lead to positive outcomes from the trials, which would likely have a positive impact on the company's stock.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100